The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)
Abstract
Purpose Two recombinant IFN-beta products have been approved for the treatment of multiple sclerosis, a glycosylated form with the predicted natural amino acid sequence (IFN-beta-1a) and a non-glycosylated form that has a Met-1 deletion and a Cys-17 to Ser mutation (IFN-beta-1b). The structural basis for activity differences between IFN-beta-1a and IFN-beta-1b, is determined. Methods In vitro antiviral, antiproliferative and immunomodulatory assays were used to directly compare the two IFN-beta products. Size exclusion chromatography (SEC), SDS-PAGE, thermal denaturation, and X-ray crystallography were used to examine structural differences. Results IFN-beta-1a was 10 times more active than IFN-beta-1b with specific activities in a standard antiviral assay of 20 x 10(7) IU/mg for IFN-beta-1a and 2 x 10(7) IU/mg for IFN-beta-1b. Of the known structural differences between IFN-beta-1a and IFN-beta-1b, only glycosylation affected in vitro activity. Deglycosylation of IFN-beta-1a produced a decrease in total activity that was primarily caused by the formation of an insoluble disulfide-linked IFN precipitate. Deglycosylation also resulted in an increased sensitivity to thermal denaturation. SEC data for IFN-beta-1b revealed large, soluble aggregates that had reduced antiviral activity (approximated at 0.7 x 10(7) IU/mg). Crystallographic data for IFN-beta-1a revealed that the glycan formed H-bonds with the peptide backbone and shielded an uncharged surface from solvent exposure. C…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have demonstrated that proper glycosylation profiles can improve recombinant protein properties such as increase their stability and half-life in blood circulation and decrease their immunogenicity (Ashwell and Harford, 1982;Runkel et al., 1998;Ghaderi et al., 2010;Ghaderi et al., 2012;Jefferis, 2016a;Jefferis, 2016b;Kuriakose et al., 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Runkel et al., 1998
Citations
Cites
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,197
Stewart, W. E. (1979) · Springer eBooks · doi:10.1007/978-3-7091-3432-0 · Cited by 1,165
Rademacher, T. W., Parekh, R. B., & Dwek, R. A. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004033 · Cited by 1,144
Lis, H., & Sharon, N. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18347.x · Cited by 840
The interferon system. A bird's eye view of its biochemistry.
Sen, G. C., & Lengyel, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42719-6 · Cited by 633
Glycoproteins: what are the sugar chains for?
Paulson, J. C. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90062-5 · Cited by 461
Influence of the Carbohydrate Moiety on the Stability of Glycoproteins
Wang, C., Eufemi, M., Turano, C., & GIARTOSIO, A. (1996) · Biochemistry · doi:10.1021/bi9517704 · Cited by 344
Flagged first, then by citations
Cited by
Sorted by citations
Instability, stabilization, and formulation of liquid protein pharmaceuticals
Wang, W. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00152-0 · Cited by 1,094
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,007
Protein aggregation and its inhibition in biopharmaceutics
Wang, W. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.014 · Cited by 1,023
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Goodin, D. S., Frohman, E. M., Garmany, G. P., Halper, J., Likosky, W., LUBLIN, F. D., Silberberg, D. H., Stuart, W. H., & van den Noort, S. (2002) · Neurology · doi:10.1212/wnl.58.2.169 · Cited by 797
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. H. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 643
Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins
Sinclair, A. M., & Elliott, S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20319 · Cited by 461
Monk, P., Marsden, R., Tear, V. J., Brookes, J. L., Batten, T. N., Mankowski, M., Gabbay, F. J., Davies, D. E., Holgate, S. T., Ho, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30511-7 · Cited by 441
Glycosylation of Therapeutic Proteins
Solá, R. J., & Griebenow, K. H. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 443
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
Delivery of interferon-β to the monkey nervous system following intranasal administration
Thorne, R. G., Hanson, L. R., Ross, T. M., Tung, D., & Frey, W. H. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.013 · Cited by 258
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Kuriakose, A., Chirmule, N. B., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 231
Sørensen, P. S., Deisenhammer, F., Duda, P. W., Hohlfeld, R., Myhr, K., Palace, J. A., Polman, C. H., Pozzilli, C., Ross, C., & for the EFNS Task Force on Anti‐IFN‐β Antibodies in Multiple Sclerosis (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01386.x · Cited by 226
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Oxidation of Therapeutic Proteins and Peptides: Structural and Biological Consequences
Torosantucci, R., Schöneich, C., & Jiskoot, W. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1199-9 · Cited by 222
Immunological mechanism underlying the immune response to recombinant human protein therapeutics
Sauerborn, M., Brinks, V., Jiskoot, W., & Schellekens, H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.001 · Cited by 206
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 187
Goodin, D., Frohman, E. M., Hurwitz, B. J., O'Connor, P. W., Oger, J. J.-F., Reder, A. T., & Stevens, J. C. (2007) · Neurology · doi:10.1212/01.wnl.0000258545.73854.cf · Cited by 173
van Beers, M. M. C., & Bardor, M. (2012) · Biotechnology Journal · doi:10.1002/biot.201200065 · Cited by 173
Production of therapeutic antibodies with controlled fucosylation
Yamane‐Ohnuki, N., & Satoh, M. (2009) · mAbs · doi:10.4161/mabs.1.3.8328 · Cited by 173
Zhou, Q., & Qiu, H. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.029 · Cited by 169
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Glycosylation: impact, control and improvement during therapeutic protein production
Costa, A. R., Rodrigues, M. E., Henriques, M., Oliveira, R., & Azeredo, J. (2013) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.793649 · Cited by 159
Enhanced Production of Monomeric Interferon-β by CHO Cells through the Control of Culture Conditions
Rodriguez, J., Spearman, M., Huzel, N., & Butler, M. (2008) · Biotechnology Progress · doi:10.1021/bp049807b · Cited by 145
Bertolotto, A. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.2.148 · Cited by 145
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
Inhaled proteins: Challenges and perspectives
Depreter, F., Pilcer, G., & Amighi, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.031 · Cited by 145
FTIR and nDSC as Analytical Tools for High-Concentration Protein Formulations
Matheus, S., Frieß, W., & Mahler, H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0142-8 · Cited by 132
Macrophages and cytokines in the early defence against herpes simplex virus
Ellermann‐Eriksen, S. (2005) · Virology Journal · doi:10.1186/1743-422x-2-59 · Cited by 134
Barnard, J. G., Babcock, K., & Carpenter, J. F. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23415 · Cited by 127
Pepinsky, R. B., LePage, D., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E. T., Hochman, P. S., & Martin, P. L. (2001) · PubMed · Cited by 119
Self-citationSakamoto, I., Tezuka, K., Fukae, K., Ishii, K., Taduru, K., Maeda, M., Ouchi, M., Yoshida, K. J., Nambu, Y., Igarashi, J., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2109079 · Cited by 116
van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0451-4 · Cited by 114
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges
Jiskoot, W., Kijanka, G., Randolph, T. W., Carpenter, J. F., Koulov, A. V., Mahler, H., Joubert, M. K., Jawa, V., & Narhi, L. O. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.02.031 · Cited by 115
Nejadnik, M. R., Randolph, T. W., Volkin, D. B., Schöneich, C., Carpenter, J. F., Crommelin, D. J. A., & Jiskoot, W. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.04.005 · Cited by 119
Glycosylation of therapeutic proteins in different production systems
Werner, R. G., Kopp, K., & Schlueter, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00199.x · Cited by 113
The structure of human interferon- ? : implications for activity
Karpusas, M., Whitty, A., Runkel, L., & Hochman, P. S. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050248 · Cited by 111
Self-citationAggregation of therapeutic proteins
Wang, W., & Roberts, C. J. (2010) · Wiley eBooks · Cited by 104
Wadhwa, M., Bird, C., Dilger, P., Gaines-Das, R. E., & Thorpe, R. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00206-0 · Cited by 104
Neutralising antibodies to interferon beta during the treatment of multiple sclerosis
Giovannoni, G. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.465 · Cited by 104
Immunogenicity of interferon beta: differences among products
Bertolotto, A., Deisenhammer, F., Gallo, P., & S�rensen, P. S. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1204-7 · Cited by 103
Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy
Nelissen, I., Martens, E., den Steen, P. E. V., Proost, P., Ronsse, I., & Opdenakker, G. (2003) · Brain · doi:10.1093/brain/awg129 · Cited by 100
Diversity and Relatedness Among the Type I Interferons
Chen, J., Baig, E., & Fish, E. N. (2004) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2004.24.687 · Cited by 99
Muneeruddin, K., Nazzaro, M., & Kaltashov, I. A. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02982 · Cited by 98
Engineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals
Seth, G., Hossler, P., Yee, J. C., & Hu, W. (2006) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_017 · Cited by 99
Bertolotto, A., Malucchi, S., Milano, E., Castello, A., Capobianco, M. A. N., & Mutani, R. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00182-x · Cited by 95
Kaltashov, I. A., Bobst, C. E., Abzalimov, R. R., Berkowitz, S. A., & Houde, D. J. (2009) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2009.10.013 · Cited by 92
van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0172-0 · Cited by 90
Formulation and Stability of Cytokine Therapeutics
Lipiäinen, T., Peltoniemi, M., Sarkhel, S., Yrjönen, T., Vuorela, H. J., Urtti, A. O., & Juppo, A. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24243 · Cited by 90
van Beers, M. M. C., Jiskoot, W., & Schellekens, H. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0086 · Cited by 86
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 87
Ealy, A. D., Larson, S. F., Liu, L., Alexenko, A. P., Winkelman, G. L., Kubisch, H. M., Bixby, J. A., & Roberts, R. M. (2001) · Endocrinology · doi:10.1210/endo.142.7.8249 · Cited by 83
Beta-interferon for multiple sclerosis
Rudick, R. A., & Goelz, S. E. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.002 · Cited by 80
Self-citationTherapeutic apheresis in neurological disorders
Weinstein, R. S. (2000) · Journal of Clinical Apheresis · doi:10.1002/(sici)1098-1101(2000)15:1/2 · Cited by 78
Pepinsky, R. B., LePage, D., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E. T., Hochman, P. S., & Martin, P. L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29633-6 · Cited by 77
Self-citationKivisäkk, P., Alm, G. V., Fredrikson, S., & Link, H. (2000) · European Journal of Neurology · doi:10.1046/j.1468-1331.2000.00002.x · Cited by 76
Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta
Hermeling, S., Jiskoot, W., Crommelin, D. J. A., Bornæs, C., & Schellekens, H. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4578-z · Cited by 72
Interferon Beta: From Molecular Level to Therapeutic Effects
Abdolvahab, M. H., Mofrad, M. R. K., & Schellekens, H. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.06.001 · Cited by 73
Sung, C., Nardelli, B., LaFleur, D. W., Blatter, E. E., Corcoran, M. L., Olsen, H. S., Birse, C. E., Pickeral, O. K., Zhang, J., Shah, D., et al. (2003) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900360520423 · Cited by 71
N-Linked Glycosylation of Antibody Fragments in Escherichia coli
Lizak, C., Fan, Y., Weber, T. C., & Aebi, M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100511k · Cited by 69
Perspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae
Barolo, L., Abbriano, R. M., Commault, A. S., George, J., Kahlke, T., Fabris, M., Padula, M. P., Lopez, A., Ralph, P. J., & Pernice, M. (2020) · Cells · doi:10.3390/cells9030633 · Cited by 66
Improving Immunotherapy Through Glycodesign
Buettner, M. J., Shah, S. R., Saeui, C. T., Ariss, R., & Yarema, K. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02485 · Cited by 68
Interferon-β1afor the treatment of multiple sclerosis
Clerico, M., Contessa, G., & Durelli, L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.535 · Cited by 64
Herndon, R. M., Rudick, R. A., Munschauer, F. E., Mass, M. K., Salazar, A. Μ., Coats, M. E., Labutta, R. J., Richert, J. R., COHAN, S. L., Genain, C. P., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1209oa · Cited by 64
Glycosylation Shapes the Efficacy and Safety of Diverse Protein, Gene and Cell Therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Frohman, E. M. (2003) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00008-7 · Cited by 62
Antonelli, G., Simeoni, E., Bagnato, F. R., Pozzilli, C., Turriziani, O., Tesoro, R., Marco, P. D., Gasperini, C., Fieschi, C., & DIANZANI, F. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00185-9 · Cited by 62
Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A., Pozzilli, C., & Antonelli, G. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00173-4 · Cited by 61
A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events
Brandes, D. W., Callender, T., Lathi, E. S., & O’Leary, S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802569455 · Cited by 60
Brickelmaier, M., Hochman, P. S., Baciu, R., Chao, B. H., Cuervo, J. H., & Whitty, A. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00073-3 · Cited by 60
Self-citationThe implications of immunogenicity for protein-based multiple sclerosis therapies
Cohen, B. A., Oger, J., Gagnon, A. W., & Giovannoni, G. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.08.003 · Cited by 57
High productivity of human recombinant beta-interferon from a low-temperature perfusion culture
Rodriguez, J., Spearman, M. A., Tharmalingam, T., Sunley, K., Lodewyks, C. L., Huzel, N. J., & Butler, M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.09.959 · Cited by 62
‘Biogenerics’: the off-patent biotech products
Schellekens, H., & Ryff, J. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01967-2 · Cited by 56
Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis
Gilli, F., Marnetto, F., Caldano, M., Sala, A., Malucchi, S., Sapio, A. D., Capobianco, M. A. N., & Bertolotto, A. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.08.006 · Cited by 54
Alsenaidy, M. A., Jain, N. K., Kim, J. H., Middaugh, C. R., & Volkin, D. B. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00039 · Cited by 53
Kosloski, M. P., Miclea, R. D., & Balu‐Iyer, S. V. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9119-y · Cited by 51
Scagnolari, C., Bellomi, F., Turriziani, O., Bagnato, F. R., Tomassini, V., Lavolpe, V., Ruggieri, M., Bruschi, F., Meucci, G., Dicuonzo, G., et al. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/107999002753536176 · Cited by 51
Spearman, M. A., Rodriguez, J., Huzel, N. J., & Butler, M. (2005) · Biotechnology Progress · doi:10.1021/bp0498084 · Cited by 50
Svilenov, H. L., Markoja, U., & Winter, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.004 · Cited by 49
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge
Zettl, U. K., Hecker, M., Aktaş, O., Wagner, T. B., & Rommer, P. S. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1426462 · Cited by 49
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
Bastard, P., Gervais, A., Taniguchi, M., Saare, L., Särekannu, K., Voyer, T. L., Philippot, Q., Rosain, J., Bizien, L., Asano, T., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231353 · Cited by 51
Antonetti, F., Finocchiaro, O., Mascia, M., Terlizzese, M., & Jaber, A. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260475696 · Cited by 47
Courtney, A., Treadaway, K., Remington, G. M., & Frohman, E. M. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2008.09.014 · Cited by 46
Hartung, H., Munschauer, F., & Schellekens, H. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01104.x · Cited by 46
Arduini, R. M., Li, Z., Rapoza, A., Gronke, R. S., Hess, D. M., Wen, D., Miatkowski, K., Coots, C., Kaffashan, A., Viseux, N., et al. (2003) · Protein Expression and Purification · doi:10.1016/j.pep.2003.11.004 · Cited by 46
Self-citationA high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
Yao, H., Cai, H., Li, T., Zhou, B., Qin, W., Lavillette, D., & Li, D. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009328 · Cited by 46
Torosantucci, R., Sharov, V. S., van Beers, M. M. C., Brinks, V., Schöneich, C., & Jiskoot, W. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300665u · Cited by 44
The bioactivity and fractionation of peptide hydrolysates in cultures of CHO cells
Spearman, M. A., Lodewyks, C. L., Richmond, M. E. I., & Butler, M. (2014) · Biotechnology Progress · doi:10.1002/btpr.1930 · Cited by 44
Review: Neutralizing antibodies against interferon-beta
Sørensen, P. S. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608095144 · Cited by 43
Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth
van Koetsveld, P. M., Vitale, G., de Herder, W. W., Feelders, R. A., van der Wansem, K., Waaijers, M., van Eijck, C. H. J., Speel, E. M., Croze, E., van der Lely, A. J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0620 · Cited by 41
Using measurements of neutralizing antibodies: the challenge of IFN‐β therapy
Hesse, D., & Sørensen, P. S. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01769.x · Cited by 41
The Function of the Human Interferon-β1a Glycan Determined in Vivo
Dissing‐Olesen, L., Thaysen‐Andersen, M., Meldgaard, M., Højrup, P., & Finsen, B. R. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138263 · Cited by 40
Harada, H., Tamaoka, A., Kohno, Y., Mochizuki, A., & Shoji, S. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00082-9 · Cited by 40
Pereiro, P., Costa, M. M., Díaz‐Rosales, P., Dios, S., Figueras, A. J., & Novoa, B. (2014) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2014.03.006 · Cited by 40
Baker, D. P., Pepinsky, R. B., Brickelmaier, M., Gronke, R. S., Hu, X. S., Olivier, K., Lerner, M., Miller, L., Crossman, M., Nestorov, I. A., et al. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0092 · Cited by 38
Self-citationCurrent and Future Therapies Targeting the Immune System in Multiple Sclerosis
Loleit, V., Biberacher, V., & Hemmer, B. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140617104332 · Cited by 37
Molecular dynamics simulation for rational protein engineering: Present and future prospectus
Rouhani, M., Khodabakhsh, F., Norouzian, D., Cohan, R. A., & Valizadeh, V. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.06.009 · Cited by 38
Interferon-β in the treatment of relapsing–remitting multiple sclerosis
Revel, M. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00085-8 · Cited by 38
Immunogenicity of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse315 · Cited by 38
Metadata
- Authors
- Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., & Goelz, S. E.
- Affiliations
- Biogen (United States) (US)
- Corresponding author
- Runkel, Laura
- ORCID
- Whitty, Adrian
- Venue
- Pharmaceutical Research
- Published
- 1998-04
- Volume
- 15
- Issue
- 4
- Pages
- 641-649
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W329292291
- Cited by
- 304
- References
- 34
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 10 · 2020: 11 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 16 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 13
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Keywords
- interferon-beta, glycosylation, recombinant interferon, multiple sclerosis, antiviral activity, protein stability, thermal denaturation, protein aggregation, disulfide bonds, protein structure
- MeSH terms
- Interferon beta-1a, Interferon beta-1b, Adjuvants, Immunologic, Antiviral Agents, Base Sequence, Cell Division, Cell Line, Cysteine, Encephalomyocarditis virus, Glycosylation, Humans, Major Histocompatibility Complex, Molecular Sequence Data, Mutation, Recombinant Proteins, Serine, Interferon-beta, Cardiovirus Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review